Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Boswellic acid has anti-inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells.

Barbarisi M, Barbarisi A, De Sena G, Armenia E, Aurilio C, Libutti M, Iaffaioli RV, Botti G, Maurea N, Quagliariello V.

Phytother Res. 2019 Jun;33(6):1670-1682. doi: 10.1002/ptr.6354. Epub 2019 Mar 28.

PMID:
30924205
2.

Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology.

Pascarella G, Capasso A, Nardone A, Triassi M, Pignata S, Arenare L, Ascierto P, Curvietto M, Maiolino P, D'Aniello R, Montanino A, Laudato F, De Feo G, Botti G, Perrone F, Petrillo A, Cavalcanti E, Lastoria S, Maurea N, Morabito A.

PLoS One. 2019 Jan 8;14(1):e0210330. doi: 10.1371/journal.pone.0210330. eCollection 2019.

3.

Oil Core-PEG Shell Nanocarriers for In Vivo MRI Imaging.

Calcagno V, Vecchione R, Quagliariello V, Marzola P, Busato A, Giustetto P, Profeta M, Gargiulo S, Cicco CD, Yu H, Cassani M, Maurea N, Mancini M, Pellegrino T, Netti PA.

Adv Healthc Mater. 2019 Feb;8(3):e1801313. doi: 10.1002/adhm.201801313. Epub 2019 Jan 7.

PMID:
30614638
4.

[Edoxaban in patients with atrial fibrillation and cancer].

Maurea N, Riva L.

G Ital Cardiol (Rome). 2018 Sep;19(9 Suppl 1):13S-19S. doi: 10.1714/2989.29923. Italian.

PMID:
30284558
5.

[Venous thromboembolism and atrial fibrillation in patients with cancer].

Maurea N, Riva L.

G Ital Cardiol (Rome). 2018 Sep;19(9 Suppl 1):3S-6S. doi: 10.1714/2989.29921. Italian. No abstract available.

PMID:
30284556
6.

Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity.

Quagliariello V, Vecchione R, Coppola C, Di Cicco C, De Capua A, Piscopo G, Paciello R, Narciso V, Formisano C, Taglialatela-Scafati O, Iaffaioli RV, Botti G, Netti PA, Maurea N.

Nutrients. 2018 Sep 14;10(9). pii: E1304. doi: 10.3390/nu10091304.

7.

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine.

De Lorenzo C, Paciello R, Riccio G, Rea D, Barbieri A, Coppola C, Maurea N.

Onco Targets Ther. 2018 Apr 19;11:2241-2250. doi: 10.2147/OTT.S157294. eCollection 2018.

8.

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production.

Riccio G, Antonucci S, Coppola C, D'Avino C, Piscopo G, Fiore D, Maurea C, Russo M, Rea D, Arra C, Condorelli G, Di Lisa F, Tocchetti CG, De Lorenzo C, Maurea N.

Front Physiol. 2018 Feb 6;9:38. doi: 10.3389/fphys.2018.00038. eCollection 2018.

9.

Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study.

Calabrese V, Menna P, Annibali O, Armento G, Carpino A, Cerchiara E, Greco C, Marchesi F, Spallarossa P, Toglia G, Reggiardo G, Minotti G; Collaborators.

Chemotherapy. 2018;63(2):55-63. doi: 10.1159/000486761. Epub 2018 Feb 9. Erratum in: Chemotherapy. 2018 Apr 10;63(2):64.

PMID:
29428939
10.

Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.

Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N.

Cancer Treat Rev. 2018 Feb;63:135-143. doi: 10.1016/j.ctrv.2017.11.009. Epub 2017 Dec 6. Review.

11.

Enhanced Drug Delivery into Cell Cytosol via Glycoprotein H-Derived Peptide Conjugated Nanoemulsions.

Fotticchia T, Vecchione R, Scognamiglio PL, Guarnieri D, Calcagno V, Di Natale C, Attanasio C, De Gregorio M, Di Cicco C, Quagliariello V, Maurea N, Barbieri A, Arra C, Raiola L, Iaffaioli RV, Netti PA.

ACS Nano. 2017 Oct 24;11(10):9802-9813. doi: 10.1021/acsnano.7b03058. Epub 2017 Aug 28.

PMID:
28820568
12.

ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary.

Tarantini L, Gulizia MM, Di Lenarda A, Maurea N, Giuseppe Abrignani M, Bisceglia I, Bovelli D, De Gennaro L, Del Sindaco D, Macera F, Parrini I, Radini D, Russo G, Beatrice Scardovi A, Inno A.

Eur Heart J Suppl. 2017 May;19(Suppl D):D370-D379. doi: 10.1093/eurheartj/sux019. Epub 2017 May 2.

13.

[ANMCO/AICO/AIOM Consensus document: Clinical and management pathways in cardio-oncology].

Tarantini L, Gulizia MM, Di Lenarda A, Maurea N, Abrignani MG, Bisceglia I, Bovelli D, De Gennaro L, Del Sindaco D, Macera F, Parrini I, Radini D, Russo G, Scardovi AB, Inno A.

G Ital Cardiol (Rome). 2017 Jan;18(1):14-66. doi: 10.1714/2628.27023. Italian.

PMID:
28287211
14.

Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?

De Vecchis R, Noutsias M, Ariano C, Cesaro A, Cioppa C, Giasi A, Maurea N.

J Clin Med Res. 2017 Apr;9(4):266-272. doi: 10.14740/jocmr2933w. Epub 2017 Feb 21. Review.

15.

The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials.

De Vecchis R, Cantatrione C, Mazzei D, Barone A, Maurea N.

J Clin Med Res. 2017 Feb;9(2):130-142. doi: 10.14740/jocmr2851w. Epub 2016 Dec 31.

16.

Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking.

Coppola C, Riccio G, Barbieri A, Monti MG, Piscopo G, Rea D, Arra C, Maurea C, De Lorenzo C, Maurea N.

Onco Targets Ther. 2016 Nov 2;9:6785-6794. eCollection 2016.

17.

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.

Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e93-e104. Review.

PMID:
27755247
18.

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.

Spallarossa P, Maurea N, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e84-e92. Review.

PMID:
27755246
19.

Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.

Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e19-e26. Review.

PMID:
27755239
20.

Pathophysiology of anthracycline cardiotoxicity.

Mele D, Tocchetti CG, Pagliaro P, Madonna R, Novo G, Pepe A, Zito C, Maurea N, Spallarossa P.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e3-e11. Review.

PMID:
27755237

Supplemental Content

Loading ...
Support Center